Get the Stockscreener App
13.05
3.65%
0.46
Pre-market:
12.90
-0.15
-1.15%
Eyepoint Inc stock is traded at $13.05, with a volume of 647.23K.
It is up +3.65% in the last 24 hours and down -26.52% over the past month.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$12.59
Open:
$12.7
24h Volume:
647.23K
Relative Volume:
0.48
Market Cap:
$1.09B
Revenue:
$31.37M
Net Income/Loss:
$-231.96M
P/E Ratio:
-4.1256
EPS:
-3.1632
Net Cash Flow:
$-243.39M
1W Performance:
-4.33%
1M Performance:
-26.52%
6M Performance:
-1.06%
1Y Performance:
+109.13%
1-Day Range:
$12.70
$13.33
1-Week Range:
$12.07
$13.97
52-Week Range:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
13.05 | 1.05B | 31.37M | -231.96M | -243.39M | -3.1632 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
EyePoint Pharmaceuticals at RBC Conference: Strategic Progress in Ophthalmology By Investing.com - Investing.com Canada
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference - Yahoo Finance
EyePoint (EYPT) surges 15.2%: Is this an indication of further gains? - MSN
EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
EyePoint (EYPT) Sues Ocular Therapeutix (OCUL) Over False Claims - GuruFocus
EyePoint files a lawsuit against Ocular (EYPT:NASDAQ) - Seeking Alpha
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 earnings call transcript - MSN
EyePoint, Inc. Files Complaint Against Ocular Therapeutix—Key Details from Latest 8-K SEC Filing - Minichart
How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In Focus - Yahoo Finance
Eyepoint files complaint against Ocular Therapeutix in Middlesex County Superior Court - marketscreener.com
On March 20, 2026, EyePoint has officially filed a lawsuit against biotechnology company Ocular Therapeutix in the Superior Court of Middlesex County, Massachusetts, USA. - Bitget
EyePoint Sues Ocular Therapeutix Over Alleged Defamation - TipRanks
A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance - Sahm
Behavioral Patterns of EYPT and Institutional Flows - Stock Traders Daily
Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients - Traders Union
EyePoint Pharmaceuticals Q4 2025 earnings preview - MSN
Risk Hedge: What is the long term forecast for EyePoint Pharmaceuticals Inc stock2026 Geopolitical Influence & Safe Entry Point Identification - baoquankhu1.vn
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Eyepoint (EYPT) CEO Duker buys $19,723 in company stock By Investing.com - Investing.com Australia
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment - AOL.com
Insider Buying: Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys 1,500 Shares of Stock - MarketBeat
Eyepoint (EYPT) CEO Duker buys $19,723 in company stock - Investing.com
Family trust of EyePoint (EYPT) CEO acquires 1,500 company shares - Stock Titan
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus - TipRanks
Guggenheim reiterates EyePoint stock rating on Duravyu safety data By Investing.com - Investing.com Canada
Guggenheim reiterates EyePoint stock rating on Duravyu safety data - Investing.com
EyePoint (EYPT) Issues Stock Options to New Employees as Hiring Incentives - GuruFocus
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com Nigeria
Parkman Healthcare Partners Acquires New Stake in EyePoint Pharmaceuticals - Intellectia AI
Suvretta Capital Management LLC Sells 611,376 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Rosalind Advisors Inc. Acquires Shares of 650,000 Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com Nigeria
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 9.1%Here's Why - MarketBeat
Jefferies Financial Group Inc. Purchases Shares of 140,000 Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Winners Losers: Should I hold or sell EyePoint Pharmaceuticals Inc now2026 Review & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
EyePoint files automatic mixed securities shelf - MSN
H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress - Investing.com Nigeria
J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Aug Breakouts: Can EyePoint Pharmaceuticals Inc expand its profit margins2026 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities - The Globe and Mail
EyePoint Pharmaceuticals Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations - Markets Mojo
EyePoint (EYPT) Sees Target Price Raise by Citigroup to $35 | EY - GuruFocus
Citigroup Boosts Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $35.00 - MarketBeat
EyePoint stock rating maintained at Outperform by Mizuho - Investing.com
EyePoint stock rating maintained at Outperform by Mizuho By Investing.com - Investing.com South Africa
What is HC Wainwright's Estimate for EYPT Q1 Earnings? - MarketBeat
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):